Quantum Genomics appoints Professor Toshiro Fujita as member of its Scientific Advisory Board (AcT)

Paris & New York, June 30, 2017

Quantum Genomics (Alternext - FR0011648971 - ALQGC), a biopharmaceutical company with the mission of developing new therapies for unmet medical needs in the field of cardiovascular diseases, is pleased to announce the appointment of Professor Toshiro Fujita as member of its Scientific Advisory Board.

Professor Toshiro Fujita is Professor of the Department of Clinical Epigenetics, RCAST, The University of Tokyo and Director, CREST, JST Strategic Basic Research Program. He conducted numerous researches in salt-sensitive hypertension. He is member of HBPR Leadership Committee, former President of the Japanese Society of Hypertension and Vice-President of the International Society of Hypertension.

Together with Professor Mark Caulfield, Professor Keith C. Ferdinand and Professor Alexandre Persu, he will provide recommendations regarding the Research & Development programs of Quantum Genomics.

Lionel Ségard, Chairman & CEO of Quantum Genomics, says:

“We are very pleased to strengthen our scientific advisory board with Professor Toshiro Fujita, an internationally renowned specialist in hypertension, who conducted numerous researches in salt-sensitive hypertension and in chronic kidney disease hypertensive population. His expertise in both resistant hypertension and the Japanese pharmaceutical market will be an important asset for Quantum Genomics.”

ABOUT QUANTUM GENOMICS

Quantum Genomics is a biopharmaceutical company with the mission of developing new therapies for unmet medical needs in the field of cardiovascular diseases, especially hypertension and heart failure.

The Company is developing a new therapeutic approach based on BAPAI (Brain Aminopeptidase A Inhibition). This is the result of more than 20 years of academic research in the laboratories of the Collège de France, INSERM, CNRS and the University of Paris Descartes.

Quantum Genomics is listed on the Alternext market in Paris (ISIN code FR0011648971, Ticker ALQGC).

The Company has offices in Paris, France, and New York, NY, USA. For more information, please visit www.quantum-genomics.com

CONTACTS

Quantum Genomics

Lionel Ségard

Chairman & Chief Executive Officer
+33 1 85 34 77 77
 

Quantum Genomics
Marc Karako
CFO – Investor Relations
+33 1 85 34 77 75

marc.karako@quantum-genomics.com

ACTUS finance & communication (Europe)

Jean-Michel Marmillon

Press Relations

+33 1 53 67 36 73

jmmarmillon@actus.fr

Edison Advisors (U.S.)

Tirth Patel

Investor Relations

+1 (646) 653-7035

tpatel@edisongroup.com

Source : Actusnews